Longer-Term All-Cause and Cardiovascular Mortality With Intensive Blood Pressure Control

Authors:

Abstract
Hypertension is a leading modifiable risk factor for cardiovascular disease (CVD).1 Meta-analyses of randomized trials have shown that pharmacological blood pressure (BP) lowering reduces the risk of major cardiovascular events across the spectrum of initial BP.2,3 The Systolic Blood Pressure Intervention Trial (SPRINT) showed that intensive treatment, defined by a systolic BP (SBP) target less than 120 mm Hg, reduced the risk of incident CVD and all-cause mortality compared with treatment to an SBP target of less than 140 mm Hg.4 Similar results, in favor of a lower SBP target of 110 mm Hg to less than 130 mm Hg, were also recently observed for a composite cardiovascular outcome in the Strategy of Blood Pressure Intervention in the Elderly Hypertensive Patients (STEP) trial.5 However, both trials were stopped after a median follow-up of approximately 3.3 years. The longer-term effect of intensive treatment on cardiovascular and all-cause mortality after either trial (ie, the legacy effect)6 has not been evaluated.

This publication has 25 references indexed in Scilit: